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Duration of fever and serious bacterial infections
in children: a systematic review
Gijs Elshout1*, Miriam Monteny1, Johannes C van der Wouden1, Bart W Koes1 and Marjolein Y Berger2
Abstract
Background: Parents of febrile children frequently contact primary care. Longer duration of fever has been related
to increased risk for serious bacterial infections (SBI). However, the evidence for this association remains
controversial. We assessed the predictive value of duration of fever for SBI.
Methods: Studies from MEDLINE, Embase and Cochrane databases (from January 1991 to December 2009) were
retrieved. We included studies describing children aged 2 months to 6 years in countries with high Haemophilus
influenzae type b vaccination coverage. Duration of fever had to be studied as a predictor for serious bacterial
infections.
Results: Seven studies assessed the association between duration of fever and serious bacterial infections; three of
these found a relationship.
Conclusion: The predictive value of duration of fever for identifying serious bacterial infections in children remains
inconclusive. None of these seven studies was performed in primary care. Studies evaluating the duration of fever
and its predictive value in children in primary care are required.
Background
Fever is very common among young children and a fre-
quent reason for parents to contact primary care [1].
Febrile children usually have self-limiting viral infec-
tions, and serious infections in need of medical interven-
tion are rare. In primary care, clinical markers are the
most appropriate evaluation tools in febrile children. In
some studies, the duration of fever prior to presentation
has been shown to be a predictor of serious bacterial
infection (SBI) [2-6]. However, the evidence for this
association remains a subject of discussion [7]. For
example, in the practice guideline for the management
of febrile children in primary care, the Dutch College of
General Practitioners (NHG) recommends that children
with more than three days of fever at presentation
should be seen by a general practitioner (GP) [7]. In
contrast, the NICE guideline for feverish illness in chil-
dren in the UK states that duration of fever should not
be used to predict the likelihood of serious illness, other
than Kawasaki disease [8]. Both guidelines base these
recommendations on studies performed in secondary
and tertiary care, which may not be applicable for
primary care settings.
Since the introduction of the Haemophilus influenzae
type b (Hib) conjugate vaccine during the last two dec-
ades, the prevalence of Hib-induced infections has
decreased [9]. This might have consequences for the
association between duration of fever and SBI. Gaining
more insight into the course of fever in the post-Hib era
is essential for the evaluation and management of febrile
children in primary and secondary care.
Therefore, we conducted a systematic review of stu-
dies on duration of fever in children aged two months
to six years, in the post-Hib era. We aimed at answering
the question: what is the association between duration
of fever and an SBI in febrile children?
Methods
Identification and selection of the literature
A systematic search of the literature was made from
January 1991 to December 2009 in the MEDLINE,
Embase and Cochrane databases. Since Hib vaccination
was not widely distributed before 1991 [10], the search
was restricted to the years after 1990. Sensitive search
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strategies (’clinical queries’) were used for prognostic
studies [11], diagnostic studies [12] and randomized
controlled trials (RCTs) [13]. The following keywords
and MeSH-headings were used: ‘fever’, ‘preschool child’,
‘infant’, ‘childhood’, ‘course*’, ‘duration’, ‘disease’, ‘infec-
tion’, ‘bacterial infection’, ‘bacterial infections’, ‘serious
bacterial infection*’, ‘mortality’, ‘child hospitalization’,
and ‘hospitalization’ (see additional file 1, Table S1).
Reference lists of selected publications were checked to
identify additional relevant publications.
To identify eligible studies, titles and abstracts result-
ing from the search strategy were screened indepen-
dently by two teams of reviewers (MM/GE and MYB/
JCvdW). Studies had to meet the following criteria:
1) The design of the study was a prospective cohort
study, cross-sectional study or RCT.
2) The majority of participants were children aged
two months to six years (or an identifiable and sepa-
rately analyzed subgroup of at least ten children
aged two months to six years).
3) Enrolment occurred in a country with adequate
Hib vaccination coverage, i.e. ≥ 80% according to
WHO/UNICEF estimates [10], during at least 50%
of the enrolment period.
4) The outcome measure was duration of fever
(prior to enrolment) as prognostic factor for SBI.
5) In case of SBI, eligible diagnoses included bactere-
mia, sepsis, bacterial meningitis, bacterial pneumo-
nia, infectious arthritis, osteomyelitis, cellulitis, soft
tissue infection, pyelonephritis, urinary tract infec-
tion, bacterial gastroenteritis, tonsillitis, or otitis
media.
Studies focusing on immunocompromized children or
fever syndromes were excluded. Studies in countries
outside Europe, North America, Australia or New Zeal-
and were excluded, because the etiology, prevalence and
presentation of febrile illnesses differ significantly in
these countries.
Data extraction
Two teams of reviewers (MM/GE and MYB/JCvdW)
independently extracted data from the selected studies
using standardized forms. The extracted data concerned
design, setting, study population, outcome measures and
prognostic factors.
Quality assessment
Two teams of reviewers (MM/GE and MYB/JCvdW)
assessed the methodological quality of the studies inde-
pendently, by means of a modified version of the criteria
list for prognostic studies as developed by Hayden et al.
[14] Since cross-sectional studies were also included, we
added an item concerning the independent assessment
of duration of fever and SBI diagnosis. The list consisted
of 22 items (Table 1) that were scored positive (+),
negative (-), unclear (?) or not applicable (NA). Dis-
agreement between the reviewers was discussed in a
consensus meeting.
Table 1 Items included in the methodological quality
assessment
Study participation
1 Setting of recruitment is described
2 Moment of identification is described and equal for all included
children (inception cohort)
3 Percentage participation of eligible children is described
4 Inclusion and exclusion criteria are described and age, fever and
relevant co-morbidity are reported
5 Baseline study sample is described for key characteristics age and
sex
Study attrition
6 Number of loss to follow-up in cohort study/RCT is <20%, or the
number missing for analysis (the difference between number
included and number analyzed) in cross-sectional studies is <20%
7 Reasons for loss to follow-up/missing for analysis are provided
8 Key characteristics (at least age and sex) of participants lost to
follow-up/missing for analysis do not differ significantly from the
study sample
Prognostic factor measurement
9 Prognostic factor duration of fever: method of measurement is
described and valid (thermometer)
10 Prognostic factor duration of fever: duration prior to presentation is
described
11 Prognostic factor SBI: definition of diagnosis is described and valid
12 If continuous variables are used, they are reported as continuous
variables or appropriate cut-off points (not data dependent) are
used
Outcome measurement
13 A clear definition of the outcome (duration of fever, SBI or
hospitalization) is provided
14 Method and setting of outcome measurement are the same for all
study participants
15 SBI was assessed independently from the assessment of fever
Confounding measurement and account
16 Antipyretics use before and/or during the study is assessed and
reported
17 Antibiotics use before and/or during the study is assessed and
reported
18 Level of illness is measured and measurement method is
appropriate (e.g. Yale score) and the same for all children
19 The potential confounders antipyretics use, antibiotics use and
illness level are accounted for in the study design or analysis
Analysis
20 There is data presentation of the prognostic factors duration of
fever and/or SBI
21 The association of prognostic factor and outcome is given in
percentages or means/medians, or in OR/RRs with confidence
interval/SD, or calculation of these measures is possible
22 A multivariate model is used in the analysis
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Inter-assessor agreement of the methodological quality
assessment was calculated using kappa scores [15]. The
total quality score for each study was calculated by
counting all positively scored criteria (maximum 22) and
dividing this number by the number of applicable items.
High quality was defined as a score of 50% or higher.
Analysis
The studies included in this review were considered too
heterogeneous (regarding setting, definition of fever and
of SBI, and presentation of the results) to pool the data.
Therefore, a best-evidence synthesis was used to sum-
marize the value of prognostic factors. Four levels of
evidence were defined, based on Sackett et al. [16] and
Ariens et al. [17] (see additional file 2, Table S2). Only
significant associations were considered in this synthesis,
defined by a threshold of p ≤ 0.05 or odds ratios (OR)
with a confidence interval (CI) not including 1.0.
Significance of differences between groups was
assessed using chi-square analysis. When not reported
but sufficient data were available, the association
between prognostic factors and outcome was calculated
as ORs with 95% CIs.
Results
The search strategy yielded 5458 citations, of which 96
could not be excluded based on title and abstract. Full-
text versions of these 96 citations were retrieved. Figure 1
presents a flow chart of the process of identification and
exclusion. Seven publications were included [18-24].
All seven studies were cross-sectional studies and were
performed in an emergency room setting. Three studies
concerned children aged 1 to 36 months [18,21,22], and
two studies included children aged 3 to 36 months
[20,24]. The two remaining studies concerned children
aged 2 to 6 months [19], or 0 to 18 years [23]. The med-
ian or mean ages of the children in the studies were all
within our two months to six years inclusion criterion.
Table 2 gives the results of the methodological quality
assessment after consensus. The overall kappa before
consensus was 0.73, indicating substantial agreement
[15]. In all cases of initial disagreement, consensus was
achieved between the two teams of reviewers. Six studies
were of high quality according to our predefined criter-
ion; the median score was 63 (range 45-74%), one study
had a score of 45% [24]. The details of the included stu-
dies are given in additional file 3, Table S3. ORs were cal-
culated using data from the studies by Pratt et al. [22].
Predictive value of duration of fever for SBI
Seven studies, including a total of 1644 children, pro-
vided information on the predictive value of duration of
fever at presentation for identifying SBI [18-24]. All
seven studies were cross-sectional, five of which were
performed in the USA [19-23], one in France [24], and
one in Spain [18]. Fever was defined as a minimal tem-
perature of 38°C [18-20] or 39°C [21,22,24]. One study
investigated hyperpyrexia defined as ≥41.1°C [23]. Tem-
perature was measured rectally [19,23], axillary [18], or
at an unspecified location [20-22,24]. The definition of
the outcome of SBI varied between occult bacterial
infections only, and localized or invasive bacterial infec-
tions including occult bacteremia. Between and within
the various studies, the diagnostic tests for SBIs (e.g.
lumbar puncture) were performed in all patients or only
in selected patients.
One study showed a significant univariate association
of duration of fever at presentation with occult bacter-
ial infection [19] and another study showed a signifi-
cant association in a multivariate model [20]. One
study of low quality provided an overall median prior
duration of fever of 24 (range 0.25-192) hours versus
4.6 (± 3.13) hours in children with occult bacteremia
[24]. However, no p-value or CI was provided. The
remaining four studies showed no significant associa-
tion, either in the univariate [18,22,23] or the multi-
variate analysis [21]. Therefore, according to our
classification (Table 2), the level of evidence for the
association between the duration of fever at presenta-
tion and a SBI is inconclusive.
Discussion
Summary of main findings
The predictive value of duration of fever at presentation
for SBI remains contradictory and hence inconclusive.
Strengths and limitations of this study
The number of studies in this review is relatively small,
with only a few studies available for our objective.
Although we initially retrieved a high number of publi-
cations using a sensitive search strategy, many studies
did not fulfill our inclusion criteria. This reflects the
lack of information on the duration of fever in children
in the post-Hib era, making it difficult to draw firm con-
clusions on the duration of fever and its predictive value
for SBI.
Trautner et al. showed that duration of fever is not
predictive for SBI [23]. However, their study included
children with hyperpyrexia only, defined as a rectal tem-
perature of ≥41.1°C, measured at the emergency room.
Thereby, their study population is not representative for
patients seen in general practice. By focusing on a sub-
group with hyperpyrexia, other factors may better pre-
dict SBI in this latter study population than duration of
fever.
None of the studies controlled for use of antipyretics
or antibiotics, which may have confounded the results
of these studies.
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All studies were performed in secondary and tertiary
care settings. Due to selected and different study popu-
lations, the results found may not be relevant for a pri-
mary care setting. For example, in the study of Trautner
et al., seven of the twenty patients with a SBI had a pre-
existing condition.
Comparison with existing literature
A recent review described the diagnostic value of clinical
features to identify serious infections in children [25];
however, they included fewer and different studies
addressing duration of fever or illness. We excluded
four out of five studies, because they did not meet our
inclusion criteria for age [26], Hib coverage [2], study
design [3], and fever [27]; this makes the results of the
reviews less comparable. Van den Bruel et al. [25]
concluded that duration of fever or illness is not a
strong predictor for serious infections, which is in line
with our conclusion.
Implications for future research or clinical practice
An explanation for the inconclusive findings for a pre-
dictive value of duration of fever might be the heteroge-
neity of the definition of SBI. One study reported a
trend of shorter duration of fever and the possibility of
bacteremia compared to the overall group [24]. Other
studies, that did not meet the inclusion criterion for Hib
vaccination coverage, found similar results [28,29]. It is
plausible that the predictive value of the duration of
fever depends on the specific SBI under study. A com-
parable explanation was put forward in the NICE guide-
line [8]. For example, bacteremia, meningitis and sepsis
Potentially relevant citations screened for retrieval of full publication (n=5458)
Excluded citations based on title and abstract (n=5362)
Full publications retrieved for further evaluation (n=96)
7 studies included in the current review
Excluded publications (n=89):
Age criterion (n=26)
Hib vaccine coverage criterion (n=19)
Relation duration of fever and SBI not studied (n=34)
Retrospective design (n=5)
Country of study is African, Asian, or South-American (n=3)
Not an original study (n=2)
Figure 1 Identification and inclusion of studies in the present review.
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are SBIs that can develop relatively quickly, whereas
bacterial pneumonia or urinary tract infection may
develop over a longer period of time. All the other stu-
dies in our review, looking at duration of fever as pre-
dictor for SBI, included bacteremia, but they may have
diluted the prognostic value of duration of fever by ana-
lyzing bacteremia combined with other SBIs. However,
in general practice a broad spectrum of both slow and
quick-developing SBIs will be presented. Therefore, rela-
tions other than a linear association between duration of
fever and SBI may be more appropriate. Multivariate
analyses considering the interaction between duration of
fever and other variables (e.g. level of illness, age), and
stratification for different kinds of SBIs, may yield more
data about the relationship between duration of fever
and risk of SBI. Observational studies are needed to test
this hypothesis and thereby elucidate the duration of
fever and its significance in the management of febrile
children in primary care. Until then, it seems appropri-
ate not to use duration of fever to assess the risk of SBI
in febrile children in primary care.
Conclusion
The predictive value of duration of fever at presentation
for SBI remains contradictory and hence inconclusive.
None of these seven studies was performed in primary
care. Studies evaluating the duration of fever and its
predictive value in children in primary care are required.
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Table 2 Results of quality assessment of the methodology of the included studies
Item (see Table 1) Pulliam et al.25 Isaacman et al.22 Fernandez Lopez et al.20 Hsiao et al.21 Trautner et al.27 Pratt et al.26 Guen et al.28
1 + + + + + + +
2 + + + + + + +
3 - - - + + - -
4 + - + - + + +
5 + - - - + + -
6 + + ? + NA + ?
7 NA NA ? + NA NA NA
8 NA NA ? ? NA NA ?
9 - - + + + - -
10 + + + + + + +
11 NA NA NA NA NA NA NA
12 - + + + + ? +
13 + + + - + + -
14 + + + ? - - ?
15 + + ? ? + + +
16 - - - - - - ?
17 + + + - - + +
18 + - - + - + -
19 - - - - - - -
20 + + + + + + +
21 + + + + + + +
22 + + - - - - -
Total score (%) 74 63 52 52 67 63 45
+; positive, -; negative, ?; unclear, NA; not applicable.
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